Asthma isn’t a single disease. It’s an umbrella term for several conditions that all involve inflamed, narrowed airways but differ in what triggers them, which immune cells drive them, and how they respond to treatment. Understanding which type you have matters because the wrong approach can leave symptoms uncontrolled for years. Here’s a breakdown of the major types and what sets each one apart.
Allergic Asthma
Allergic asthma is the most common form. Symptoms flare when you inhale allergens like dust mites, pet dander, pollen, or mold. Your immune system produces an antibody called IgE in response to these otherwise harmless substances, and the combination of IgE and allergens triggers a cascade of chemical signals that inflame and swell the airways. People with allergic asthma often have a history of other allergic conditions like eczema or hay fever, and symptoms tend to follow seasonal or environmental patterns.
Because allergic asthma is driven by a well-understood immune pathway, it generally responds well to inhaled corticosteroids and, in more severe cases, targeted biologic therapies that block IgE or the inflammatory signals behind it. Allergy testing through skin pricks or blood work can confirm the diagnosis and identify your specific triggers.
Non-Allergic Asthma
Some people develop asthma with no allergic component at all. Their symptoms are triggered instead by viral or bacterial infections, cold air, stress, strong odors, acid reflux (GERD), or changes in weather. Non-allergic asthma tends to appear for the first time in adulthood rather than childhood, and allergy tests come back negative. The airways still inflame and tighten, but through different immune pathways, which can make treatment trickier. Standard inhaled corticosteroids still help many people, but the response is less predictable than in allergic asthma.
Exercise-Induced Bronchoconstriction
Exercise-induced bronchoconstriction (EIB) causes airway narrowing during or shortly after physical activity. The trigger is surprisingly mechanical: when you breathe hard during exercise, your airways lose water as they humidify large volumes of air. That water loss has two effects. First, it cools the airway lining, and the rapid rewarming afterward causes blood vessels to swell. Second, the loss of water increases the concentration of salts on the airway surface, which prompts cells to release chemicals that make the surrounding muscle contract.
Cold, dry air makes EIB worse because the airways have to work harder to warm and humidify each breath. Swimming in a heated, humid pool, by contrast, is one of the better-tolerated forms of exercise. EIB can occur in people who have no other asthma symptoms, and it’s particularly common in endurance athletes and winter sport competitors. A short-acting inhaler used 15 to 20 minutes before exercise prevents symptoms in most cases.
Cough-Variant Asthma
Cough-variant asthma produces a persistent dry cough as the only symptom. There’s no wheezing, no chest tightness, no shortness of breath. Because the cough looks like so many other conditions, from post-nasal drip to acid reflux, this type often goes undiagnosed for months or years. People bounce between doctors treating a “chronic cough” before anyone tests for asthma. A trial of asthma medication that resolves the cough is often what clinches the diagnosis. Left untreated, cough-variant asthma can progress to classic asthma with the full range of symptoms.
Occupational Asthma
Occupational asthma develops from repeated exposure to irritants or sensitizing agents at work. Hundreds of substances can cause it, but the most well-documented include diisocyanates (found in spray painting, polyurethane production, and foam manufacturing), flour and grain dust (in bakeries and farming), and proteins from coffee beans, tea, and other plant materials.
The pattern is often the giveaway: symptoms improve on weekends and vacations, then return on workdays. Some people develop symptoms within weeks of a new exposure, while others work around an agent for years before their immune system becomes sensitized. Early identification is critical because continued exposure leads to permanent airway damage. Removing yourself from the exposure, or at minimum reducing it with better ventilation and protective equipment, is the most important treatment step.
Aspirin-Exacerbated Respiratory Disease
Aspirin-exacerbated respiratory disease (AERD), also called Samter’s Triad, is a specific syndrome combining three features: asthma, chronic sinus disease with recurring nasal polyps, and sensitivity to aspirin and similar pain relievers that block an enzyme called COX-1. Taking aspirin or ibuprofen triggers severe asthma attacks, nasal congestion, and sometimes facial flushing within minutes to hours.
About 9% of all adults with asthma have AERD, but that number jumps to 30% among those who also have nasal polyps. It typically appears in young adulthood and tends to be a more aggressive form of asthma. The underlying problem is an overproduction of inflammatory molecules in the airways. People with AERD need to avoid aspirin and most over-the-counter anti-inflammatory drugs, though some undergo a supervised desensitization process that allows them to tolerate aspirin over time, which can actually improve their symptoms.
How Inflammation Defines Asthma Types
Beyond these clinical categories, doctors increasingly classify asthma by which immune cells are driving the inflammation. This matters because it predicts how well standard treatments will work.
Type 2-High (Eosinophilic) Asthma
The majority of asthma cases are driven by a branch of the immune system called the Type 2 pathway. In this type, white blood cells called eosinophils accumulate in the airways, recruited by signaling molecules (particularly IL-4, IL-5, and IL-13). This is the immune machinery behind both allergic asthma and many cases of non-allergic asthma that still show elevated eosinophils.
Type 2-high asthma is the best-understood form. It responds well to inhaled corticosteroids, and for people with severe disease, biologic medications that block the specific signals driving eosinophil production have transformed treatment. These targeted therapies can cut severe flare-ups by roughly 50% in the right patients.
Type 2-Low (Neutrophilic) Asthma
About 1 in 5 adults with asthma have a different inflammatory profile dominated by neutrophils rather than eosinophils. These patients tend to be older, are less likely to have allergies, and often have bacteria colonizing their airways. Smoking is a strong driver of this type, pushing the immune system toward neutrophilic inflammation through a distinct set of chemical signals.
This is the frustrating form of asthma. Standard corticosteroids, the backbone of asthma treatment, work poorly here. Therapies designed to reduce neutrophil activity have shown limited success in severe cases. Certain antibiotics with anti-inflammatory properties have shown more promise, reducing both airway inflammation and flare-ups. But compared to eosinophilic asthma, treatment options are far more limited, and research is still catching up.
How Doctors Tell These Types Apart
One of the most useful tools for sorting out asthma types is a simple breath test that measures fractional exhaled nitric oxide (FeNO). Nitric oxide levels in your breath rise when the Type 2 inflammatory pathway is active. In adults, a FeNO reading above 50 parts per billion strongly suggests eosinophilic inflammation and predicts a good response to corticosteroids. A reading below 25 ppb makes eosinophilic inflammation unlikely, and doctors may consider alternative diagnoses or a non-eosinophilic asthma type.
FeNO also helps guide biologic therapy. Patients with readings of 25 ppb or higher show significantly better responses to certain targeted treatments, while those below that threshold see little benefit. Interestingly, FeNO doesn’t predict response to medications that directly target eosinophils, confirming that eosinophil activity and nitric oxide production run on separate pathways, even though they often overlap.
Beyond FeNO, doctors use blood eosinophil counts, allergy testing, lung function tests, and detailed history-taking to piece together which type of asthma someone has. The pattern of your triggers, the age your symptoms started, whether you have nasal polyps or allergies, and how you’ve responded to past treatments all contribute to the picture.
Severe Versus Difficult-to-Treat Asthma
When asthma doesn’t respond to treatment, doctors distinguish between two categories that look similar but have very different solutions.
Difficult-to-treat asthma is uncontrolled despite being prescribed medium- or high-dose inhaled corticosteroids alongside a second controller medication. But the problem often lies outside the lungs. Poor inhaler technique, inconsistent medication use, untreated acid reflux, ongoing allergen exposure, or smoking can all make asthma appear resistant to treatment when the underlying disease would actually respond if these factors were addressed.
Severe asthma is a smaller subset where the disease remains uncontrolled even after all those contributing factors have been identified and corrected, and the patient is truly adherent to optimized therapy. Roughly 5 to 10% of people with asthma fall into this category. These patients often need biologic therapies or other advanced treatments, and their care typically involves a specialist. The distinction matters because the first step for any uncontrolled asthma isn’t necessarily stronger medication. It’s making sure the basics are working.